High capacity screening of pooled compounds: Identification of the active compound without re-assay of pool members

High capacity screening of pooled compounds: Identification of the active compound without re-assay of pool members

A matrix‐based compound pooling and deconvolution method has been developed that significantly increased the efficiency of a high‐capacity screening program. This method is based on screening pools of 10 compounds. The matrix used to assemble the pools resulted in each compound being assayed twice—e...

Full description

Saved in:
Bibliographic Details
Published in:Drug development research Vol. 37; no. 2; pp. 80 - 85
Main Authors: Devlin, James J., Liang, Amy, Trinh, Lan, Polokoff, Mark A., Senator, David, Zheng, Wei, Kondracki, Jason, Kretschmer, Peter J., Morser, John, Lipson, Samuel E., Spann, Richard, Loughlin, John A., Dunn, Kathryn V., Morrissey, Michael M.
Format: Journal Article
Language:English
Published: New York John Wiley & Sons, Inc 01-02-1996
Wiley-Liss
Subjects:
Biological and medical sciences
biological assay
bombesin receptors
factor Xa
General pharmacology
Medical sciences
nitric oxide
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
Drug
Serine endopeptidases
Enzyme
Enzyme inhibitor
Coagulation Factor Xa
Nitric-oxide synthase
Research and development
Gastrin releasing peptide
Screening
Investigation method
Hydrolases
Pool
Oxidoreductases
Antagonist
Pharmaceutical industry
Proteinases
Biological receptor
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A matrix‐based compound pooling and deconvolution method has been developed that significantly increased the efficiency of a high‐capacity screening program. This method is based on screening pools of 10 compounds. The matrix used to assemble the pools resulted in each compound being assayed twice—each time with a completely different set of pooled compounds. The active compound in an active pool was accurately predicted by determining which compound was present in an active pool both times that a pool containing that compound was tested. This has eliminated the need to re‐assay each individual member of active pools. This approach has been tested with a set of 6,680 compounds in three different assays: inhibition of Factor Xa, inhibition of gastrin‐releasing peptide receptor binding, and inhibition of nitric oxide synthase (isoform II). Thus significant time is saved not only by pooling the compounds for the initial assay but also by avoiding the need to re‐assay all compounds in active pools. Moreover, no false negatives occurred in these assays—an important consideration from a drug discovery perspective. © 1996 Wiley‐Liss, Inc.
Bibliography:istex:371F8E28F0589F984D9D2A5151675D8B5E2B30D5
ArticleID:DDR3
ark:/67375/WNG-GXW32HRH-J
ISSN:0272-4391
1098-2299
DOI:10.1002/(SICI)1098-2299(199602)37:2<80::AID-DDR3>3.0.CO;2-H